Praluent (Alirocumab) Pediatric Dosing: What Clinicians Need to Know for Children Under 12

What Is Alirocumab and Why Does Pediatric Dosing Matter?

Alirocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), blocking its ability to degrade LDL receptors on hepatocytes. More LDL receptors remain on the cell surface, clearing more LDL-C from circulation. The FDA approved alirocumab in adults in July 2015 for heterozygous familial hypercholesterolemia (HeFH) and for adults with established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering beyond maximally tolerated statin therapy. [1]

Children under 12 represent a narrow but high-stakes population. Familial hypercholesterolemia affects approximately 1 in 250 individuals in its heterozygous form and roughly 1 in 300 to 000 in its homozygous form, according to data from the FH Foundation and published prevalence analyses. [2] Left untreated, HoFH can produce coronary artery disease before age 20. HeFH, even in its less severe form, deposits arterial plaque for decades before diagnosis, making early intervention biologically compelling.

The tension for clinicians is straightforward: the biologic rationale for early PCSK9 inhibition is strong, but the formal pediatric pharmacokinetic and long-term safety dataset for alirocumab in children under 12 remains incomplete. Prescribers must weigh the severity of the lipid phenotype against the absence of label support for this age band.

Current FDA Approval Status for Patients Under 12

The FDA has not approved alirocumab for any patient under 18 years of age in the United States as of July 2025. The approved US indications cover adults only. [1] Evolocumab (Repatha), the competing PCSK9 inhibitor from Amgen, received FDA approval in 2021 for HoFH in patients 10 years and older and for HeFH in patients 13 and older, establishing a precedent for PCSK9 inhibitor labeling in adolescents. [3]

The European Medicines Agency granted alirocumab approval for HeFH in children aged 8 and older in 2022, based on pharmacokinetic modeling and the phase 3 ODYSSEY KIDS trial data. [4] That regulatory gap between Europe and the United States is clinically important for US practitioners: a European drug approval does not constitute US labeling, and US prescribers cannot cite EMA labeling as a substitute for FDA approval.

For children under 12 in the United States, any alirocumab use is off-label. Off-label prescribing is legal and sometimes medically appropriate, but it requires documented informed consent, specialist oversight, and a clear benefit-risk analysis. The American Academy of Pediatrics policy on off-label medication use calls for "individualized risk-benefit analysis and parental informed consent" in all such cases. [5]

ODYSSEY KIDS: The Core Pediatric Trial Dataset

The ODYSSEY KIDS trial (NCT02392559) is the primary source of alirocumab pharmacokinetic and safety data in younger patients. The trial enrolled children and adolescents aged 8 to 17 years with HeFH across three weight-based cohorts: under 25 kg, 25 to 50 kg, and over 50 kg. Participants received open-label alirocumab at doses ranging from 50 mg every 4 weeks to 150 mg every 2 weeks, with dosing adjusted to body weight group. [6]

At 24 weeks, LDL-C reductions across cohorts ranged from approximately 35% to 52% from baseline, consistent with the adult ODYSSEY program results. Injection-site reactions occurred in about 18% of participants but were mostly mild. No serious hepatic adverse events attributable to alirocumab were observed over the primary 24-week period, and a 52-week open-label extension confirmed sustained LDL-C lowering without unexpected safety signals. [6]

The trial did not enroll children under 8 years of age, which is why the current evidence base and the EMA label both set age 8 as the lower boundary. Children under 8 (and therefore all children under 12 in the US, given the absence of any FDA pediatric label) fall outside the published trial dataset for alirocumab.

Why Under-12 Dosing Has No Standard Protocol

No phase 3 randomized controlled trial has evaluated alirocumab specifically in children under 8 years old. Pharmacokinetic modeling from ODYSSEY KIDS suggests that weight-based dosing (approximately 3 mg/kg every 2 weeks, or adjusted intervals based on response) may produce adequate drug exposure in younger, lighter children, but this remains modeling-level evidence. [6]

The FDA's Pediatric Research Equity Act (PREA) requires manufacturers to conduct pediatric studies for drugs likely to be used in children, but timelines for completion vary widely. Regeneron and Sanofi have not, as of this writing, published a completed phase 2 or phase 3 trial in children under 8. Clinicians seeking to use alirocumab in a child under 12 should search ClinicalTrials.gov for currently enrolling studies before making any prescribing decision.

Growth and developmental considerations add a layer of uncertainty absent in adult prescribing. PCSK9 plays a role in central nervous system neuronal development and lipid metabolism during early childhood, as shown in preclinical work published in the Journal of Lipid Research. [7] Whether chronic PCSK9 inhibition during ages 4 to 11 affects neurological development is not yet established in human longitudinal data. This is not a reason to categorically withhold treatment in severe HoFH cases where life-threatening cardiovascular risk exists, but it does argue for specialist-led decision-making and long-term developmental surveillance.

Adult and Adolescent Dosing as the Clinical Reference Point

Because under-12 dosing lacks an established protocol, understanding the approved adult regimen is the necessary starting framework for any off-label discussion.

Adults (approved US label): Alirocumab is initiated at 75 mg subcutaneous injection every 2 weeks. If LDL-C response is inadequate at 4 to 8 weeks, the dose may be titrated to 150 mg every 2 weeks. For patients who prefer less frequent dosing, 300 mg every 4 weeks is an alternative, equivalent in total monthly dose to 150 mg Q2W. [1]

Adolescents aged 8 and older (EMA label only): ODYSSEY KIDS weight-band dosing was:

• Body weight <25 kg: 50 mg every 4 weeks (may increase to 75 mg every 4 weeks)
• Body weight 25 to 50 kg: 75 mg every 4 weeks (may increase to 150 mg every 4 weeks)
• Body weight >50 kg: 75 mg every 2 weeks (may increase to 150 mg every 2 weeks)

These EMA-based weight-band doses are the closest available reference for any clinician considering alirocumab in a child under 12 under exceptional circumstances, as they represent the only published dose-finding data below adult weight ranges.

The adult ODYSSEY OUTCOMES trial enrolled 18,924 post-acute coronary syndrome patients and demonstrated a 15% relative reduction in major adverse cardiovascular events (MACE) with alirocumab vs. placebo (hazard ratio 0.85 to 95% CI 0.78-0.93, P<0.001) over a median follow-up of 2.8 years. [8] That outcomes data justifies aggressive LDL-C lowering by any approved mechanism in high-risk patients, but its direct applicability to pre-pubertal children is extrapolated rather than proven.

Heterozygous vs. Homozygous FH: Different Urgency Levels

The clinical urgency differs substantially between HeFH and HoFH in children, and that urgency shapes the off-label risk-benefit calculus.

Children with HoFH have two defective LDL-receptor alleles. They can have LDL-C levels exceeding 400 mg/dL from birth. The 2021 European Atherosclerosis Society (EAS) guidance on HoFH states that "LDL-C lowering should begin as early as possible, ideally before age 5" in confirmed HoFH cases. [9] Statins and ezetimibe remain first-line even in HoFH, but their efficacy is blunted because LDL-receptor function is absent or minimal. PCSK9 inhibitors work primarily through increasing LDL-receptor recycling, which means they have reduced efficacy in patients with no functional LDL receptors (receptor-negative HoFH). In receptor-defective HoFH (residual LDL-receptor activity of 2-25%), alirocumab may still produce meaningful LDL-C reductions of 20-30%. [9]

Children with HeFH have one functional LDL-receptor allele. Their LDL-C typically ranges from 160 to 400 mg/dL. In this group, statin therapy started at age 8 to 10 (per American Heart Association / American College of Cardiology pediatric lipid guidelines) is the established first-line approach. [10] PCSK9 inhibitors are reserved for cases where maximally tolerated statin plus ezetimibe therapy fails to achieve adequate LDL-C lowering or where statin intolerance is documented.

The Role of Statins and Ezetimibe Before Alirocumab

Before any clinician considers alirocumab in a child under 12, guideline-directed medical therapy must be optimized. The ACC/AHA 2018 Cholesterol Guideline and the National Lipid Association guidelines both require documented statin therapy before PCSK9 inhibitor initiation in adults, and pediatric lipid guidelines follow a similar hierarchy. [10, 11]

For children with HeFH aged 8 to 10, rosuvastatin at 5 to 20 mg daily or atorvastatin at 10 to 20 mg daily are standard options, each supported by randomized controlled trial data in this age group. [12] Ezetimibe 10 mg daily may be added when statin therapy alone is insufficient, reducing LDL-C by an additional 15 to 20% in children. [13] Only after this stair-step approach fails to meet LDL-C targets does a specialist typically consider escalation to a PCSK9 inhibitor in a child under 12.

Monitoring Requirements in Younger Patients

Whether alirocumab is used on-label in adults or off-label in a young child, specific monitoring parameters apply. In younger patients, those parameters are more extensive because the long-term developmental dataset is absent.

Lipid panel: Obtain a fasting lipid panel 4 to 8 weeks after initiating alirocumab or after any dose change. If LDL-C falls below 25 mg/dL on two consecutive measurements, reassess the necessity of therapy. Very low LDL-C levels were associated with small but statistically increased hemorrhagic stroke rates in one pre-specified ODYSSEY OUTCOMES subgroup analysis, though absolute risk remained low. [8]

Hepatic function: Alirocumab does not require routine liver function testing per its FDA label, unlike some lipid-lowering agents. Still, baseline ALT/AST is reasonable in children, given the limited pediatric safety database.

Injection-site reactions: Reported in 7.2% of alirocumab-treated patients vs. 5.1% of placebo patients in the ODYSSEY LONG TERM trial (N=2,341). [14] Teach patients or caregivers to rotate injection sites and report persistent erythema or induration.

Neurocognitive surveillance: The FDA added a class-level PCSK9 inhibitor label update in 2017 noting post-marketing reports of neurocognitive adverse events (confusion, memory impairment). Formal neurocognitive testing at each annual visit is advisable for children on chronic therapy. [1]

Growth monitoring: Height, weight, and BMI percentiles should be tracked at each visit. There is no published evidence that alirocumab impairs linear growth, but the absence of evidence is not evidence of absence in a population studied for fewer than 52 weeks. [6]

Practical Administration Guidance for Caregivers

Alirocumab is supplied as a subcutaneous injection in a prefilled pen (SureClick autoinjector) or prefilled syringe in 75 mg/mL and 150 mg/mL concentrations, each in 1 mL volume. Storage is at 36-46 degrees Fahrenheit (2-8 degrees Celsius). Before injection, allow the device to sit at room temperature for 30 to 45 minutes. [1]

Injection sites include the thigh, abdomen (excluding a 2-inch radius around the navel), or upper arm. Rotate sites with each injection. For young children, the thigh is often the most accessible site and allows caregiver administration.

The device has not been tested for needle phobia or injection training in children under 8, so a clinical pharmacist or diabetes nurse educator consultation for caregiver injection training is worth arranging before the first home dose.

When to Refer to a Pediatric Lipidologist

Any child under 12 being considered for alirocumab should be evaluated by a physician with specific training in pediatric lipid disorders. The Familial Hypercholesterolemia Foundation maintains a clinician network (fhfoundation.org) where families can locate accredited lipid clinics. Referral is particularly indicated when:

• LDL-C exceeds 190 mg/dL despite maximally tolerated statin therapy for at least 3 months
• Genetic testing confirms HoFH or HeFH with a severe mutation (e.g., null LDL-receptor mutation)
• The child is under 8 years old and carries a diagnosis of HoFH
• Statin intolerance is suspected and an alternative LDL-lowering strategy is needed
• Xanthomas, corneal arcus, or other clinical signs of severe FH are present

The 2023 National Lipid Association Expert Panel on Familial Hypercholesterolemia specifies that "PCSK9 inhibitor therapy in pediatric patients should be supervised by a lipid specialist with experience in managing FH across the lifespan." [11]

Regulatory Pathway: What Could Change

The FDA's Pediatric Research Equity Act compels manufacturers to study drugs in pediatric populations when there is a reasonable expectation of use. Regeneron and Sanofi submitted pediatric study plans to the FDA as part of alirocumab's approval process. Whether a complete pediatric sNDA covering children under 8 will be submitted depends on completed trial data.

Evolocumab's approval in pediatric HoFH patients aged 10 and older (FDA 2021) and its subsequent expanded HeFH approval in adolescents 13 and older (FDA 2023) offers a roadmap. [3] If alirocumab follows a similar trajectory, a US pediatric label covering children down to age 8 (mirroring the EMA) could arrive within the next regulatory cycle. Clinicians should check the FDA Drugs@FDA database and the alirocumab prescribing information for any label updates before making prescribing decisions.

Access and Insurance Considerations

PCSK9 inhibitors carry a list price of approximately $5,500 to $6,800 per year (2024 SSR Health pricing data). Prior authorization is required by virtually every commercial payer, and many require documented statin failure, genetic confirmation of FH, or both. For children, off-label use adds a further denial risk.

The Regeneron/Sanofi Praluent CoPay Card program covers commercially insured adult patients up to a defined out-of-pocket maximum. Pediatric off-label use may not qualify. Clinicians should engage the practice's specialty pharmacy or a patient-access coordinator before the prescription reaches the pharmacy, because a surprise denial after a family has emotionally committed to a treatment plan creates unnecessary harm.

For uninsured or underinsured patients, Sanofi's Patient Assistance Program (Sanofi Cares) may provide access, but eligibility for pediatric off-label use requires direct inquiry.

Key Takeaways for Clinical Practice

Alirocumab is a well-characterized LDL-lowering agent with strong adult outcomes data, modest adolescent pharmacokinetic data from ODYSSEY KIDS, and no completed randomized trial in children under 8. The EMA label covers ages 8 and older using weight-based dosing; the US FDA label does not extend to any patient under 18 years old as of mid-2025. Statin therapy plus ezetimibe remains the established first-line regimen for children under 12 with HeFH, and alirocumab is reserved for specialist-managed cases where that regimen has failed.

For any child under 12 in whom alirocumab is being considered, the practical checklist runs as follows: confirm the FH diagnosis genetically or clinically by Simon Broome or Dutch Lipid Clinic Network criteria, document maximally tolerated statin and ezetimibe trial with LDL-C response, obtain pediatric lipidology consultation, discuss off-label status and developmental uncertainty with parents or guardians in documented informed consent, establish monitoring intervals of at least every 6 months including lipid panel and neurocognitive assessment, and register the patient in a registry (such as the CASCADE FH Registry) to contribute to the evidence base for future guidelines. [15]

The LDL-C target for a child under 12 with HeFH on combination therapy, per the 2023 NLA Expert Panel, is below 130 mg/dL, and for HoFH the target is below 100 mg/dL or at least a 50% reduction from untreated baseline. [11]